R&D JP Morgan 2024 – Xavier Duportet There were plenty of gene therapy companies around at JP Morgan 2024, and more than a few companies focused on the microbiome.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
